Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • July 2019
  • Article
  • Health Affairs

The Impact of Price Regulation on the Availability of New Drugs in Germany

By: Ariel Dora Stern, Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim and Ameet Sarpatwari
  • Format:Print
ShareBar

Abstract

The 2011 German Pharmaceutical Market Restructuring Act (“AMNOG”) subjected branded, non-rare disease drugs to price regulation based on an assessment of their clinical benefit. Assessment outcomes range from “major added benefit” to “less benefit than the appropriate comparator,” and impact price negotiations beyond the first year on the market. Using data on drugs that entered the market from 2012 to 2016, we evaluated benefit assessment findings, subsequent drug exits, and their correlates. We considered 171 drug-indication pairs, corresponding to 138 different drugs. Of these, 66 drug-indication pairs (55 different drugs) were found to have any additional benefit. Almost all drugs with any positive benefit assessment (98%) remained on the market, while drugs without a positive benefit assessment were over ten times more likely to exit (25% vs. 2%). U.S. policymakers considering how to address rapidly increasing drug costs may draw valuable lessons from the German experience.

Keywords

Regulation; Pharmaceuticals; Healthcare; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; Germany

Citation

Stern, Ariel Dora, Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim, and Ameet Sarpatwari. "The Impact of Price Regulation on the Availability of New Drugs in Germany." Health Affairs 38, no. 7 (July 2019): 1182–1187.
  • Find it at Harvard

About The Author

Ariel D. Stern

Technology and Operations Management
→More Publications

More from the Authors

    • April 18, 2022
    • Harvard Business Review (website)

    Will mRNA Technology Companies Spawn Innovation Ecosystems?

    By: Christoph Grimpe, Timo Minssen, W. Nicholson Price, II and Ariel Dora Stern
    • April 2022
    • NEJM Catalyst Innovations in Care Delivery

    AI Insurance: How Liability Insurance Can Drive the Responsible Adoption of Artificial Intelligence in Health Care

    By: Ariel Dora Stern, Avi Goldfarb and Timo Minssen
    • March 2022
    • Faculty Research

    Proximie: Using XR Technology to Create Borderless Operating Rooms

    By: Ariel D. Stern and Alpana Thapar
More from the Authors
  • Will mRNA Technology Companies Spawn Innovation Ecosystems? By: Christoph Grimpe, Timo Minssen, W. Nicholson Price, II and Ariel Dora Stern
  • AI Insurance: How Liability Insurance Can Drive the Responsible Adoption of Artificial Intelligence in Health Care By: Ariel Dora Stern, Avi Goldfarb and Timo Minssen
  • Proximie: Using XR Technology to Create Borderless Operating Rooms By: Ariel D. Stern and Alpana Thapar
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Digital Accessibility
Copyright © President & Fellows of Harvard College